9mhv

Publication Abstract from PubMed

Dual activation of the TLR7 and TLR8 pathways leads to the production of type I interferon and proinflammatory cytokines, resulting in efficient antigen presentation by dendritic cells to promote T-cell priming and antitumor immunity. We developed a novel series of TLR7/8 dual agonists with varying ratios of TLR7 and TLR8 activity for use as payloads for an antibody-drug conjugate approach. The agonist-induced production of several cytokines in human whole blood confirmed their functional activity. Structure-activity relationship studies guided by structure-based drug design are described.

Structure-Based Design of Novel TLR7/8 Agonist Payloads Enabling an Immunomodulatory Conjugate Approach.,Poudel YB, Lo JC, Norris DJ, Cox M, He L, Johnson WL, A M Subbaiah M, Mondal S, Thangavel S, Subramani L, Reddy M, Jain S, Weiss DR, Sivaprakasam P, Critton D, Mulligan D, Xie C, Dhar P, Li Y, Sega E, Yamazoe S, Gavai AV, Mathur A, Zapf CW, Chekler EP ACS Med Chem Lett. 2024 Dec 19;16(1):80-88. doi: 10.1021/acsmedchemlett.4c00463. , eCollection 2025 Jan 9. PMID:39811121^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.